CSIMarket
 


Kodiak Sciences Inc   (KOD)
Other Ticker:  
 
 

KOD's Capital Expenditures Growth by Quarter and Year

Kodiak Sciences Inc 's Capital Expenditures results by quarter and year




KOD Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 3.06 8.43 1.61
III Quarter September 0.23 8.27 4.83 0.07
II Quarter June 1.47 8.23 2.54 0.18
I Quarter March 12.17 17.46 1.24 0.15
FY   13.87 37.02 17.04 2.01



KOD Capital Expenditures third quarter 2023 Y/Y Growth Comment
Kodiak Sciences Inc reported drop in Capital Expenditures in the third quarter 2023 by -97.27% to $ 0.23 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Kodiak Sciences Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 1101.75%.

Looking into third quarter 2023 results within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Capital Expenditures growth. While Kodiak Sciences Inc ' s Capital Expenditures meltdown of -97.27% ranks overall at the positon no. 1059 in the third quarter 2023.




KOD Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -63.7 % 423.6 % 906.25 %
III Quarter September -97.27 % 71.22 % 6800 % -41.67 %
II Quarter June -82.14 % 224.02 % 1311.11 % 1700 %
I Quarter March -30.3 % 1308.06 % 726.67 % 650 %
FY   - 117.25 % 747.76 % 548.39 %

Financial Statements
Kodiak Sciences Inc 's third quarter 2023 Capital Expenditures $ 0.23 millions KOD's Income Statement
Kodiak Sciences Inc 's third quarter 2022 Capital Expenditures $ 8.27 millions Quarterly KOD's Income Statement
New: More KOD's historic Capital Expenditures Growth >>


KOD Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -63 % 74.53 % 2200 %
III Quarter September -84.63 % 0.49 % 90.16 % -61.11 %
II Quarter June -87.92 % -52.86 % 104.84 % 20 %
I Quarter March 297.71 % 107.12 % -22.98 % -6.25 %
FY (Year on Year)   - 117.25 % 747.76 % 548.39 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #19
Healthcare Sector #145
Overall #1059

Capital Expenditures Y/Y Growth Statistics
High Average Low
8614.29 % 1101.75 % -60.07 %
(Mar 31 2020)   (Sep 30 2023)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #19
Healthcare Sector #145
Overall #1059
Capital Expenditures Y/Y Growth Statistics
High Average Low
8614.29 % 1101.75 % -60.07 %
(Mar 31 2020)   (Sep 30 2023)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Kodiak Sciences Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
2227.54 % 226.15 % -87.92 %
(Sep 30 2020)  


KOD's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Kodiak Sciences Inc disclosed fall in Capital Expenditures sequentially by -84.63% to $ 0.23 millions, from $ 1.47 millions released in the previous reporting period.

Even cyclical influence could not recover the III. Quarter for the Kodiak Sciences Inc , Matteo Lambert, a business expert wrote, he voiced little caution conserning Kodiak Sciences Inc 's outlook and continued that average sequential Capital Expenditures growth is at 226.15% for the Biotechnology & Pharmaceuticals's company.

Within Biotechnology & Pharmaceuticals industry 90 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Kodiak Sciences Inc 's Capital Expenditures growth quarter on quarter, overall rank is 2920.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #91
Healthcare Sector #522
Overall #2920
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #91
Healthcare Sector #522
Overall #2920
Capital Expenditures Q/Q Growth Statistics
High Average Low
2227.54 % 226.15 % -87.92 %
(Sep 30 2020)  


KOD's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Kodiak Sciences Inc reported fall in Capital Expenditures sequentially by -84.63% to $ 0.23 millions, from $ 1.47 millions declared in the previous reporting period.

Even cyclical influence which commonly fuel III. Quarter 2023 Capital Expenditures, it plainly was not enough to recover Biotechnology & Pharmaceuticals's company III. Quarter 2023 achievement, Matteo Lambert, a business expert pointed out.

Within Biotechnology & Pharmaceuticals industry 90 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Kodiak Sciences Inc 's Capital Expenditures growth quarter on quarter, overall rank is 2920.


Kodiak Sciences Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 16.93 $ 24.97 $ 31.73 $ 37.02 $ 42.39
Y / Y Capital Expenditures Growth (TTM) -60.07 % -35.89 % -4.58 % 117.36 % 315.44 %
Year on Year Capital Expenditures Growth Overall Ranking # 68 # 30 # 14 # 49 # 131
Seqeuential Capital Expenditures Change (TTM) -32.21 % -21.3 % -14.29 % -12.67 % 8.84 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1059 # 944 # 291 # 572 # 1016




Cumulative Capital Expenditures growth Comment
Kodiak Sciences Inc 's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -60.07% year on year, at Sep 30 2023 compare to the -35.89% decrease at Jun 30 2023. If the Kodiak Sciences Inc 's fiscal year would end at Sep 30 2023, annual Capital Expenditures would be $17 millions.

Among companies within the Healthcare sector 20 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 30 to 68.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
8614.29 %
1101.75 %
-60.07 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 19
Healthcare Sector # 21
Overall # 68

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
8614.29 %
1101.75 %
-60.07 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 145
S&P 500 # 1059
Cumulative Capital Expenditures growth Comment
Kodiak Sciences Inc 's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -60.07% year on year, at Sep 30 2023 compare to the -35.89% decrease at Jun 30 2023. If the Kodiak Sciences Inc 's fiscal year would end at Sep 30 2023, annual Capital Expenditures would be $17 millions.

Among companies within the Healthcare sector 20 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 30 to 68.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
8614.29 %
1101.75 %
-60.07 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 19
Healthcare Sector # 21
Overall # 68

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
8614.29 %
1101.75 %
-60.07 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 145
S&P 500 # 1059




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
KOD's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for KOD's Competitors
Capital Expenditures Growth for Kodiak Sciences Inc 's Suppliers
Capital Expenditures Growth for KOD's Customers

You may also want to know
KOD's Annual Growth Rates KOD's Profitability Ratios KOD's Asset Turnover Ratio KOD's Dividend Growth
KOD's Roe KOD's Valuation Ratios KOD's Financial Strength Ratios KOD's Dividend Payout Ratio
KOD's Roa KOD's Inventory Turnover Ratio KOD's Growth Rates KOD's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com